CommercialCoverageMedium impact
Remote Electrical Neuromodulation for Migraines (7.01.171)
Blue Shield of California·CA · Neurology, Family Medicine, Internal Medicine +1 more·Medical Policy
Effective date
Apr 1, 2026
We identified it
Apr 1, 2026
Summary
Blue Shield of California updated their policy on Remote Electrical Neuromodulation (REN) devices like Nerivio for migraine treatment. The policy considers REN medically necessary for prevention in pediatric patients (8-17 years) and adults (18+) who meet specific headache frequency criteria, but adults must also fail 2+ medications from different drug classes first.
Action Required
Before April 1, 2026: Update prior authorization protocols for Remote Electrical Neuromodulation devices (Nerivio) for migraine prevention. Billing team must ensure documentation requirements include: ICHD-3 diagnostic criteria verification, headache frequency tracking (6-24 days per 28-day period for 3 months), and for adults 18+, documentation of insufficient response/contraindication to 2+ medications from different drug classes (anticonvulsants, antihypertensives, antidepressants, CGRP inhibitors). Note that acute migraine treatment with REN is considered investigational and not covered.